Skip to main content
Journal cover image

Cost-effectiveness of coronary artery bypass grafting plus mitral valve repair versus coronary artery bypass grafting alone for moderate ischemic mitral regurgitation.

Publication ,  Journal Article
Ferket, BS; Thourani, VH; Voisine, P; Hohmann, SF; Chang, HL; Smith, PK; Michler, RE; Ailawadi, G; Perrault, LP; Miller, MA; O'Sullivan, K ...
Published in: The Journal of thoracic and cardiovascular surgery
June 2020

The Cardiothoracic Surgical Trials Network reported that left ventricular reverse remodeling at 2 years did not differ between patients with moderate ischemic mitral regurgitation randomized to coronary artery bypass grafting plus mitral valve repair (n = 150) or coronary artery bypass grafting alone (n = 151). To address health resource use implications, we compared costs and quality-adjusted survival.We used individual patient data from the Cardiothoracic Surgical Trials Network trial on survival, hospitalizations, quality of life, and US hospitalization costs to estimate cumulative costs and quality-adjusted life years. A microsimulation model was developed to extrapolate to 10 years. Bootstrap and deterministic sensitivity analyses were performed to address uncertainty.In-hospital costs were $59,745 for coronary artery bypass grafting plus mitral valve repair versus $51,326 for coronary artery bypass grafting alone (difference $8419; 95% uncertainty interval, 2259-18,757). Two-year costs were $81,263 versus $67,341 (difference 13,922 [2370 to 28,888]), and quality-adjusted life years were 1.35 versus 1.30 (difference 0.05; -0.04 to 0.14), resulting in an incremental cost-effectiveness ratio of $308,343/quality-adjusted life year for coronary artery bypass grafting plus mitral valve repair. At 10 years, its costs remained higher ($107,733 vs $88,583, difference 19,150 [-3866 to 56,826]) and quality-adjusted life years showed no difference (-0.92 to 0.87), with 5.08 versus 5.08. The likelihood that coronary artery bypass grafting plus mitral valve repair would be considered cost-effective at 10 years based on a cost-effectiveness threshold of $100K/quality-adjusted life year did not exceed 37%. Only when this procedure reduces the death rate by a relative 5% will the incremental cost-effectiveness ratio fall below $100K/quality-adjusted life year.The addition of mitral valve repair to coronary artery bypass grafting for patients with moderate ischemic mitral regurgitation is unlikely to be cost-effective. Only if late mortality benefits can be demonstrated will it meet commonly used cost-effectiveness criteria.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

The Journal of thoracic and cardiovascular surgery

DOI

EISSN

1097-685X

ISSN

0022-5223

Publication Date

June 2020

Volume

159

Issue

6

Start / End Page

2230 / 2240.e15

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Risk Factors
  • Respiratory System
  • Randomized Controlled Trials as Topic
  • Quality-Adjusted Life Years
  • Quality of Life
  • Multicenter Studies as Topic
  • Models, Economic
  • Mitral Valve Insufficiency
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ferket, B. S., Thourani, V. H., Voisine, P., Hohmann, S. F., Chang, H. L., Smith, P. K., … Cardiothoracic Surgical Trials Network Investigators, . (2020). Cost-effectiveness of coronary artery bypass grafting plus mitral valve repair versus coronary artery bypass grafting alone for moderate ischemic mitral regurgitation. The Journal of Thoracic and Cardiovascular Surgery, 159(6), 2230-2240.e15. https://doi.org/10.1016/j.jtcvs.2019.06.040
Ferket, Bart S., Vinod H. Thourani, Pierre Voisine, Samuel F. Hohmann, Helena L. Chang, Peter K. Smith, Robert E. Michler, et al. “Cost-effectiveness of coronary artery bypass grafting plus mitral valve repair versus coronary artery bypass grafting alone for moderate ischemic mitral regurgitation.The Journal of Thoracic and Cardiovascular Surgery 159, no. 6 (June 2020): 2230-2240.e15. https://doi.org/10.1016/j.jtcvs.2019.06.040.
Ferket BS, Thourani VH, Voisine P, Hohmann SF, Chang HL, Smith PK, et al. Cost-effectiveness of coronary artery bypass grafting plus mitral valve repair versus coronary artery bypass grafting alone for moderate ischemic mitral regurgitation. The Journal of thoracic and cardiovascular surgery. 2020 Jun;159(6):2230-2240.e15.
Ferket, Bart S., et al. “Cost-effectiveness of coronary artery bypass grafting plus mitral valve repair versus coronary artery bypass grafting alone for moderate ischemic mitral regurgitation.The Journal of Thoracic and Cardiovascular Surgery, vol. 159, no. 6, June 2020, pp. 2230-2240.e15. Epmc, doi:10.1016/j.jtcvs.2019.06.040.
Ferket BS, Thourani VH, Voisine P, Hohmann SF, Chang HL, Smith PK, Michler RE, Ailawadi G, Perrault LP, Miller MA, O’Sullivan K, Mick SL, Bagiella E, Acker MA, Moquete E, Hung JW, Overbey JR, Lala A, Iraola M, Gammie JS, Gelijns AC, O’Gara PT, Moskowitz AJ, Cardiothoracic Surgical Trials Network Investigators. Cost-effectiveness of coronary artery bypass grafting plus mitral valve repair versus coronary artery bypass grafting alone for moderate ischemic mitral regurgitation. The Journal of thoracic and cardiovascular surgery. 2020 Jun;159(6):2230-2240.e15.
Journal cover image

Published In

The Journal of thoracic and cardiovascular surgery

DOI

EISSN

1097-685X

ISSN

0022-5223

Publication Date

June 2020

Volume

159

Issue

6

Start / End Page

2230 / 2240.e15

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Risk Factors
  • Respiratory System
  • Randomized Controlled Trials as Topic
  • Quality-Adjusted Life Years
  • Quality of Life
  • Multicenter Studies as Topic
  • Models, Economic
  • Mitral Valve Insufficiency